ID
16458
Description
Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC); ODM derived from: https://clinicaltrials.gov/show/NCT00153803
Link
https://clinicaltrials.gov/show/NCT00153803
Keywords
Versions (1)
- 7/17/16 7/17/16 -
Uploaded on
July 17, 2016
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Carcinoma, Non-Small-Cell Lung NCT00153803
Eligibility Carcinoma, Non-Small-Cell Lung NCT00153803
- StudyEvent: Eligibility
Description
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Description
Metastasis
Data type
boolean
Alias
- UMLS CUI [1]
- C0027627
Description
Prior treatment
Data type
boolean
Alias
- UMLS CUI [1]
- C1514463
Description
Malignant pleural or pericardial effusion
Data type
boolean
Alias
- UMLS CUI [1]
- C0080032
- UMLS CUI [2]
- C0220655
Description
Peripheral neuropathy
Data type
boolean
Alias
- UMLS CUI [1]
- C0031117
Similar models
Eligibility Carcinoma, Non-Small-Cell Lung NCT00153803
- StudyEvent: Eligibility
C1519810 (UMLS CUI [1,2])
C0220655 (UMLS CUI [2])